Literature DB >> 32359711

COVID-19 With Limb Ischemic Necrosis.

Song-Zan Qian1, Jing-Ye Pan1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32359711      PMCID: PMC7195301          DOI: 10.1053/j.jvca.2020.03.063

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


× No keyword cloud information.
To the Editor: A 53-year-old man from Wenzhou, Zhejiang, China was admitted to the First Affiliated Hospital of Wenzhou Medical University on February 1, 2020, with a 9-day history of fever with dizziness, cough, and sputum. On presentation, his temperature was 38.6°C. Laboratory tests showed a C-reactive protein concentration of 70.5 mg/L (normal range, 0.00-10.00 mg/L). Complete blood count showed elevated white blood cell count (14.9 × 109/L [normal range, 3.5-9.5 × 109/L]), neutrophils (14.2 × 109/L [1.8-6.3 × 109/L]), and monocytes (0.42 × 109/L [0.1-0.6 × 109/L]). D-dimer was 0.68 mg/L (0.00-0.5 mg/L) and platelet count was 163 × 109/L, whereas the lymphocyte count (0.25) decreased (normal range, 1.0-3.2 × 109/L). The computed tomography scan presented multiple ground-glass opacities with consolidation and bilateral lung involvement. The patient was diagnosed with coronavirus disease 2019 (COVID-19) on the basis of reverse transcription-polymerase chain reaction (RT-PCR) analysis of sputum samples. The patient developed complications including septic shock, multiple organ dysfunction syndrome, acute respiratory distress syndrome, thrombocytopenia, acute kidney injury, and catheter-related infections. The patient was treated with antibacterial, antiviral, and corticosteroid treatments, mechanical ventilation, and extracorporeal membrane oxygenation. During hospitalization, peripheral ischemia appeared on the right fingers and toes and gradually resulted in gangrene (Fig 1, Fig 2 ). Beginning on February 29th, the patient's right fingertip began to show a slight cyanosis, and on March 7th, the patient's right fingertip cyanosis continued to progress and the boundaries were clear (Fig 1). After March 10th, the patient started to develop black gangrene-like manifestations on his fingertips (Fig 2).
Fig 1

Right fingers showed cyanosis.

Fig 2

Black gangrene-like manifestations on the fingertips.

Right fingers showed cyanosis. Black gangrene-like manifestations on the fingertips. Limb ischemic necrosis is a rare but dreadful complication. Tissue necrosis in the fingers was irreversible. Although the precise mechanism of limb ischemic necrosis is unclear, this may be related to high-dose use of norepinephrine. Acute ischemic hepatitis (“shock liver”) has been identified as a potential risk factor for limb ischemic necrosis or symmetrical peripheral gangrene. The previous study shows that abnormal coagulation results, especially markedly elevated D-dimer and fibrin degradation product, are common in deaths with COVID-19. Therefore, the occurrence of limb ischemic necrosis in COVID-19 patients should be monitored closely.
  3 in total

1.  Ischemic Limb Gangrene with Pulses.

Authors:  Theodore E Warkentin
Journal:  N Engl J Med       Date:  2015-12-10       Impact factor: 91.245

2.  Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is 'shock liver' the unrecognized provocateur of ischemic limb necrosis?

Authors:  T E Warkentin; M Pai
Journal:  J Thromb Haemost       Date:  2016-01-30       Impact factor: 5.824

3.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

Authors:  Ning Tang; Dengju Li; Xiong Wang; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-03-13       Impact factor: 5.824

  3 in total
  8 in total

Review 1.  COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.

Authors:  Jae C Chang
Journal:  Vasc Health Risk Manag       Date:  2021-06-01

2.  COVID-19 and Skin Manifestations: An Overview of Case Reports/Case Series and Meta-Analysis of Prevalence Studies.

Authors:  Fatemeh Sameni; Bahareh Hajikhani; Somayeh Yaslianifard; Mehdi Goudarzi; Parviz Owlia; Mohammad Javad Nasiri; Shervin Shokouhi; Mahmood Bakhtiyari; Masoud Dadashi
Journal:  Front Med (Lausanne)       Date:  2020-10-29

Review 3.  Clinical Experience, Pathophysiology, and Considerations in the Prophylaxis and Treatment of Hypercoagulopathy of COVID-19: A Review Study.

Authors:  Leili Pourafkari; Mohammad Mirza-Aghzadeh-Attari; Armin Zarrintan; Seyed Ali Mousavi-Aghdas
Journal:  Iran J Med Sci       Date:  2021-01

Review 4.  Coronavirus disease-19: The multi-level, multi-faceted vasculopathy.

Authors:  Thiago Quinaglia; Mahsima Shabani; Ikaro Breder; Harry A Silber; João A C Lima; Andrei C Sposito
Journal:  Atherosclerosis       Date:  2021-02-15       Impact factor: 6.847

5.  Critical ischaemia of the hand and upper limb in a patient with long COVID-19 infection.

Authors:  Vivien C Lees; Jason K F Wong; Ibrahim Ibrahim
Journal:  J Hand Surg Eur Vol       Date:  2021-05-13

Review 6.  Pathogenesis of Two Faces of DVT: New Identity of Venous Thromboembolism as Combined Micro-Macrothrombosis via Unifying Mechanism Based on "Two-Path Unifying Theory" of Hemostasis and "Two-Activation Theory of the Endothelium".

Authors:  Jae C Chang
Journal:  Life (Basel)       Date:  2022-01-31

7.  Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy.

Authors:  P Del Giudice; D Boudoumi; B Le Guen; M Reverte; J Gutnecht; J P Lacour; J P Kraemer; A Motard; M Roa
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-22       Impact factor: 9.228

8.  Limb Ischemia Associated With Covid-19 and Its Treatment With Above-Knee Amputation.

Authors:  Alaaddin Oktar Üzümcügil; Nihat Demirhan Demirkiran; Süleyman Kaan Öner; Alper Akkurt; Sevil Alkan Çeviker
Journal:  Int J Low Extrem Wounds       Date:  2021-12-27       Impact factor: 1.922

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.